Walleye Capital
INBX icon

Walleye Capital’s Inhibrx INBX Stock Holding History

Walleye Capital’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-579,999
Closed -$8.93M – 4641
2024
Q4 		$8.93M Buy
579,999
+30,000
+5% +$457K 0.02% 704
2024
Q3 		$8.61M Buy
549,999
+75,000
+16% +$1.05M 0.02% 789
2024
Q2 		$6.73M Buy
+474,999
New +$7.42M 0.01% 1051

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Walleye Capital's INBX Position: Q1 2025 in Review

Walleye Capital sold out of Inhibrx (INBX) in Q1 2025, closing a stake of 579,999 shares — an estimated $8.93M sold.

Walleye Capital first reported a position in INBX in Q2 2024 and held it in 3 quarters. The position peaked at $8.93M in Q4 2024. 92 funds tracked by Wall St. Rank hold INBX as of Q1 2025.

  • Walleye Capital reported no remaining Inhibrx position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 579,999 Inhibrx shares in Q1 2025, an estimated $8.93M.
  • Walleye Capital first reported a position in Inhibrx in Q2 2024 and held it in 3 quarters.
  • Walleye Capital's Inhibrx position peaked at $8.93M in Q4 2024.
  • 92 funds tracked by Wall St. Rank held Inhibrx as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.